Research programme: cancer therapeutics - Daiichi Sankyo/Dana-Farber Cancer InstituteAlternative Names: Lung cancer therapeutics - Daiichi Sankyo
Latest Information Update: 19 Oct 2016
At a glance
- Originator Daiichi Sankyo Company; Dana-Farber Cancer Institute
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lung cancer
Most Recent Events
- 12 Oct 2016 Preclinical trials in Lung cancer in Japan